Compare Microsoft (MSFT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Novo Nordisk A/S — how do they compare? Microsoft trades at $492.31 (market cap $3.67T), while Novo Nordisk A/S trades at $44.94 (market cap $200.69B). The key difference: Microsoft is far larger — about 18.3× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| MSFT | NVO | |
|---|---|---|
Market Cap | $3.67T | $200.69B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $63.98 |
52-Week Low | $352.83 | $35.29 |
Enterprise Value | $3.65T | $215.49B |
Dividend Yield | 0.74% | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $493.95, down 1.15% on the day, with a bullish technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.74 exceeding expectations of $4.24. Revenue growth is steady, reaching $281.72B in 2025, supported by a net income margin of 40.31% and a high ROE of 34.04%. News highlights AI leadership and Azure momentum, though capital expenditure concerns persist.
Outlook remains positive with an 80.49% analyst buy rating and a consensus price target of $560.43, implying significant upside. Risks include competitive pressures in AI, high valuation multiples like a P/E of 27.52, and macroeconomic volatility. The stock's strength in cloud computing and consistent profitability underpins long-term growth potential.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
